北大医药
(000788)
| 流通市值：38.44亿 | | | 总市值：38.44亿 |
| 流通股本：5.96亿 | | | 总股本：5.96亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,534,330,245.12 | 1,008,128,208.1 | 493,957,274.92 | 2,193,796,738.18 |
| 营业收入 | 1,534,330,245.12 | 1,008,128,208.1 | 493,957,274.92 | 2,193,796,738.18 |
| 二、营业总成本 | 1,371,419,826.74 | 897,060,160.66 | 442,875,679.72 | 2,100,359,322.43 |
| 营业成本 | 1,108,500,741.03 | 716,847,403.96 | 344,356,273 | 1,481,856,314.07 |
| 税金及附加 | 8,032,811.75 | 5,060,540.19 | 2,699,338.28 | 12,730,412.54 |
| 销售费用 | 168,872,186.41 | 121,398,899.05 | 72,711,913.36 | 459,836,159.36 |
| 管理费用 | 73,033,945.27 | 44,958,871.88 | 18,277,135.85 | 117,346,017.34 |
| 研发费用 | 13,294,511.08 | 9,226,381.24 | 5,061,333.88 | 27,798,790.45 |
| 财务费用 | -314,368.8 | -431,935.66 | -230,314.65 | 791,628.67 |
| 其中:利息费用 | 2,421,511.97 | 1,779,784.41 | 990,622.36 | 6,979,225.42 |
| 其中:利息收入 | 2,880,150.25 | 2,309,706.48 | 1,274,037.7 | 6,371,352.31 |
| 加:投资收益 | - | - | - | -1,158,671.77 |
| 资产处置收益 | 185,840.72 | 185,840.72 | - | 5,887.66 |
| 资产减值损失(新) | -4,282,872.37 | -4,144,370.82 | 2,079,646.01 | -19,890,121.15 |
| 信用减值损失(新) | 2,203,524.12 | 1,289,230.04 | 399,498.41 | 2,358,651.67 |
| 其他收益 | 2,914,977.22 | 1,957,107.85 | 1,068,348.49 | 3,687,075.54 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 163,931,888.07 | 110,355,855.23 | 54,629,088.11 | 78,440,237.7 |
| 加:营业外收入 | 176,145.37 | 120,019.3 | 25,681.83 | 2,110,311.11 |
| 减:营业外支出 | 796,552.43 | 781,558.07 | 1,251,750.65 | 6,260,317.16 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 163,311,481.01 | 109,694,316.46 | 53,403,019.29 | 74,290,231.65 |
| 减:所得税费用 | 32,997,749.93 | 22,901,683.33 | 9,367,411.02 | 29,936,643.48 |
| 六、净利润 | 130,313,731.08 | 86,792,633.13 | 44,035,608.27 | 44,353,588.17 |
| 持续经营净利润 | 130,313,731.08 | 86,792,633.13 | 44,035,608.27 | 44,353,588.17 |
| 归属于母公司股东的净利润 | 130,364,988.72 | 86,825,395.85 | 44,046,906.13 | 44,356,578.25 |
| 少数股东损益 | -51,257.64 | -32,762.72 | -11,297.86 | -2,990.08 |
| (一)基本每股收益 | 0.22 | 0.15 | 0.07 | 0.07 |
| (二)稀释每股收益 | 0.22 | 0.15 | 0.07 | 0.07 |
| 九、综合收益总额 | 130,313,731.08 | 86,792,633.13 | 44,035,608.27 | 44,353,588.17 |
| 归属于母公司股东的综合收益总额 | 130,364,988.72 | 86,825,395.85 | 44,046,906.13 | 44,356,578.25 |
| 归属于少数股东的综合收益总额 | -51,257.64 | -32,762.72 | -11,297.86 | -2,990.08 |
| 公告日期 | 2024-10-26 | 2024-08-30 | 2024-04-26 | 2024-04-26 |
| 审计意见(境内) | | | | 标准无保留意见 |